Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

Compounded tirzepatide is available in non-injection formats ... Section 5 – User Journey and Market Tone Public discussions ...

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...

Tirzepatide: A dual-acting medication that combines GLP-1 and GIP ... Tirzepatide is newer to the market and may be less widely available or more expensive than semaglutide.

An injection drug known as tirzepatide, already approved by the FDA for treating Type 2 diabetes, is likely to gain approval for weight loss treatment this year. Here's what to know.

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Eli Lilly is cutting the price of its popular weight-loss drug to compete with counterfeit versions. Zepbound will be sold for $399 to $549 a month, compared to a previous list price of $1,059.

Eli Lilly's weight-loss drug Zepbound (tirzepatide) is facing a shortage in the U.S. due to increased demand, according to the FDA.

Summary. This week Lilly surpassed Johnson & Johnson to become the world's largest Pharma by market cap. That is quite astonishing given JNJ drove $95bn of revenues last year, compared to Lilly's ...